Cyclerion Therapeutics, Inc. Contracts & Agreements
39 Contracts & Agreements
- Business Finance (6 contracts)
- Business Operations (2)
- Human Resources (13)
- Intellectual Property (1)
- Real Estate (3)
- Uncategorized (14)
- Amendment to Original Offer Letter Regina Graul (Filed With SEC on August 7, 2024)
- Offer Letter, effective April 1, 2019, by and between Cyclerion Therapeutics, Inc. and Anjeza Gjino (Filed With SEC on March 5, 2024)
- Description of Securities Registered pursuant to Section 12 of the Securities Exchange Act of 1934, as amended (Filed With SEC on March 5, 2024)
- Amended and Restated Recognition Bonus Agreement, dated December 21, 2022, by and between Cyclerion Therapeutics, Inc. and Anjeza Gjino (Filed With SEC on March 5, 2024)
- Amended and Restated Recognition Bonus Agreement, dated December 21, 2022, by and between Cyclerion Therapeutics, Inc. and Cheryl Gault (Filed With SEC on March 5, 2024)
- Offer Letter to Regina Graul dated December 1, 2023 (Filed With SEC on March 5, 2024)
- Consulting Agreement with Peter Hecht dated December 1, 2023 (Filed With SEC on March 5, 2024)
- Restricted Stock Agreement with Regina Graul dated December 1, 2023 (Filed With SEC on March 5, 2024)
- Restricted Stock Agreement with Peter Hecht dated December 1, 2023 (Filed With SEC on March 5, 2024)
- Restricted Stock Agreement with Regina Graul dated January 1, 2024 (Filed With SEC on March 5, 2024)
- Restricted Stock Agreement with Peter Hecht dated January 1, 2024 (Filed With SEC on March 5, 2024)
- Separation and Release of Claims Agreement, dated October 17, 2023, by and between Cyclerion Therapeutics, Inc. and Anjeza Gjino (Filed With SEC on October 23, 2023)
- Separation Agreement, effective June 26, 2023, by and between Cyclerion Therapeutics, Inc. and Cheryl Gault (Filed With SEC on July 28, 2023)
- Form of Voting and Support Agreement (Filed With SEC on May 12, 2023)
- Asset Purchase Agreement, dated as of May 11, 2023, among the Company, JW Celtics Investment Corp. and JW Cycle Inc (Filed With SEC on May 12, 2023)
- Cyclerion Therapeutics, Inc. Executive Severance Plan (Filed With SEC on August 9, 2022)
- Non-Employee Director Compensation Plan (amended and restated as of December 17, 2021) (Filed With SEC on May 4, 2022)
- Employment Agreement, effective April 29, 2019, by and between Cyclerion GmbH and Andreas Busch (Filed With SEC on May 4, 2022)
- Offer Letter, effective April 1, 2019, by and between Cyclerion Therapeutics, Inc. and Cheryl Gault (Filed With SEC on May 4, 2022)
- Description of Securities Registered pursuant to Section 12 of the Securities Exchange Act of 1934, as amended (Filed With SEC on February 24, 2022)
- Lease Termination Agreement, dated as of April 30, 2021, by and between BMR-Rogers Street LLC and the Company (Filed With SEC on May 4, 2021)
- Description of Securities Registered pursuant to Section 12 of the Securities Exchange Act of 1934, as amended (Filed With SEC on February 25, 2021)
- Open Market Sale AgreementSM, dated September 3, 2020, by and between Cyclerion Therapeutics, Inc. and Jefferies LLC (Filed With SEC on September 3, 2020)
- Common Stock Purchase Agreement dated as of July 29, 2020, by and between Cyelerion Therapeuties, Inc. and he Investors Named Therein (Filed With SEC on August 3, 2020)
- Description of Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934, as amended (Filed With SEC on March 12, 2020)
- First Amendment to and Partial Termination of Lease Agreement Lease, dated April 1, 2019, by and between BMR-Rogers Street LLC and the Company (Filed With SEC on March 5, 2020)
- Cyclerion Therapeutics, Inc. Executive Severance Plan (Filed With SEC on September 25, 2019)
- Non-Employee Director Compensation Plan (effective June 1, 2019) (Filed With SEC on August 12, 2019)
- Separation Agreement, dated as of March 30, 2019, by and between Ironwood Pharmaceuticals, Inc. and Cyclerion Therapeutics, Inc (Filed With SEC on April 2, 2019)
- Lease, dated April 1, 2019, by and between BMR-Rogers Street LLC and Cyclerion Therapeutics, Inc (Filed With SEC on April 2, 2019)
- Transition Services Agreement, dated as of April 1, 2019, by and between Ironwood Pharmaceuticals, Inc. and Cyclerion Therapeutics, Inc (Filed With SEC on April 2, 2019)
- Offer Letter, effective April 1, 2019, by and between Cyclerion Therapeutics, Inc. and William Huyett (Filed With SEC on April 2, 2019)
- Offer Letter, effective April 1, 2019, by and between Cyclerion Therapeutics, Inc. and Mark G. Currie, Ph.D (Filed With SEC on April 2, 2019)
- Offer Letter, effective April 1, 2019, by and between Cyclerion Therapeutics, Inc. and Peter M. Hecht, Ph.D (Filed With SEC on April 2, 2019)
- Intellectual Property License Agreement, dated as of April 1, 2019, by and between Ironwood Pharmaceuticals, Inc. and Cyclerion Therapeutics, Inc (Filed With SEC on April 2, 2019)
- Development Agreement, dated as of April 1, 2019, by and between Ironwood Pharmaceuticals, Inc. and Cyclerion Therapeutics, Inc (Filed With SEC on April 2, 2019)
- Employee Matters Agreement, dated as of March 30, 2019, by and between Ironwood Pharmaceuticals, Inc. and Cyclerion Therapeutics, Inc (Filed With SEC on April 2, 2019)
- Tax Matters Agreement, dated as of March 30, 2019, by and between Ironwood Pharmaceuticals, Inc. and Cyclerion Therapeutics, Inc (Filed With SEC on April 2, 2019)
- Transition Services Agreement, dated as of April 1, 2019, by and between Cyclerion Therapeutics, Inc. and Ironwood Pharmaceuticals, Inc (Filed With SEC on April 2, 2019)
